ANGIODYNAMICS INC

Listed Company

ANGOCIK 0001275187NasdaqAcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends May 31

Period

FY 2025

Revenue

$292.50M

Net Income

$-33.99M

Total Assets

$280.14M

Equity

$182.97M

Shares Out

41.32M

Op. Cash Flow

$-10.13M

Business

AngioDynamics Inc designs, manufactures and sells medical devices and technologies used by clinicians to treat cardiovascular disease and cancer. Its product portfolio includes atherectomy systems (Auryon), thrombus management devices (AngioVac, AlphaVac, thrombolytic catheters), the NanoKnife IRE and Solero microwave ablation systems, VenaCure EVLT laser therapy, ports and vascular access products, angiographic catheters, guidewires, drainage catheters and micropuncture kits. The company reports its operations in two business segments, Med Tech and Med Device. It sells primarily in the United States through a direct sales force and internationally via a mix of direct sales and distributors to hospitals and specialist clinicians.

Summary from filing dated 2025-07-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-05-31	FY 2024 2024-05-31	FY 2023 2023-05-31	FY 2022 2022-05-31	FY 2021 2021-05-31
Net sales	292	304	339	316	291
Cost of sales (exclusive of intangible amortization)	135	149	165	150	134
Gross margin	158	155	174	166	157
Research and development	26	32	30	31	36
Sales and marketing	103	103	104	95	81
General and administrative	42	41	40	38	36
Amortization of intangibles	10	13	19	20	18
Goodwill impairment	0	159	15	0	0
Change in fair value of contingent consideration	272,000	432,000	2	1	89,000
Acquisition, restructuring and other items, net	16	53	16	9	20
Total operating expenses	198	402	225	194	192
Gain on sale of assets	0	54	0	0	—
Operating loss	−40	−192	−51	−28	−35
Interest income (expense), net	978,000	2	−3	—	—
Other income (expense), net	5	−817,000	−554,000	−790,000	92,000
Total other income (expense), net	6	797,000	−3	−1	−769,000
Loss before income tax benefit	−34	−192	−54	−30	−36
Income tax benefit	−39,000	−7	−2	−3	−5
Net loss	−34	−184	−52	−27	−32
Basic (usd per share)	−0.83	−4.59	−1.33	−0.68	−0.82
Diluted (usd per share)	−0.83	−4.59	−1.33	−0.68	−0.82
Basic (in shares)	41	40	39	39	38
Diluted (in shares)	41	40	39	39	38

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-05-31	FY 2024 2024-05-31	FY 2023 2023-05-31	FY 2022 2022-05-31	FY 2021 2021-05-31
Cash and cash equivalents	56	76	45	29	48
Accounts receivable, net of allowances of $2,215 and $2,141 respectively	43	44	53	52	35
Inventories	62	61	55	51	49
Prepaid expenses and other	8	13	5	11	9
Total current assets	168	193	164	143	141
Property, plant and equipment, Net	32	36	44	45	37
Intangible assets, net	69	77	111	152	169
Other assets	10	11	11	11	13
Total Assets	280	318	533	553	561
Accounts payable	33	38	40	28	20
Accrued liabilities	36	41	27	35	35
Current portion of contingent consideration	0	5	15	9	0
Other current liabilities	7	8	2	3	2
Total current liabilities	76	91	84	74	58
Deferred income taxes	4	5	13	16	20
Other long-term liabilities	17	16	3	5	9
Total Liabilities	97	112	154	128	122
Commitments and Contingencies (Note 17)	—	—	—	—	—
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0	0	0	0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 41,607,877 and 40,801,597 shares issued and 40,994,030 and 40,431,597 shares outstanding at May 31, 2025 and 2024, respectively	385,000	385,000	382,000	380,000	377,000
Additional paid-in capital	621	610	599	587	574
Accumulated deficit	−429	−395	−211	−158	−132
Treasury stock, 613,847 and 370,000 shares, at cost at May 31, 2025 and 2024, respectively	−7	−6	−6	−6	−6
Accumulated other comprehensive loss	−2	−4	−5	1	3
Total Stockholders' Equity	183	206	378	424	439
Total Liabilities and Stockholders' Equity	280	318	533	553	561

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-05-31	FY 2024 2024-05-31	FY 2023 2023-05-31	FY 2022 2022-05-31	FY 2021 2021-05-31
Depreciation and amortization	26	28	31	29	26
Non-cash lease expense	2	2	2	2	2
Stock based compensation	10	11	11	11	9
Gain on dispositions	0	−54	0	0	0
Transaction costs for disposition	0	−5	0	0	0
Deferred income tax provision	−988,000	−8	−2	−4	−5
Changes in accounts receivable allowances	699,000	1	695,000	118,000	207,000
Asset impairments and disposals	173,000	7	291,000	391,000	14
Write-off of other assets	0	869,000	0	0	—
Other	291,000	−62,000	−513,000	−93,000	−147,000
Accounts receivable	23,000	8	−1	−17	−4
Inventories	−1	−9	−8	−3	12
Prepaid expenses and other	3	−12	332,000	−5	−3
Accounts payable, accrued and other liabilities	−16	28	2	4	5
Net cash (used in) provided by operating activities	−10	−28	78,000	−7	24
Additions to property, plant and equipment	−4	−3	−4	−4	−5
Additions to placement and evaluation units	−6	−5	−5	−11	−9
Proceeds from sale of assets	0	135	0	0	0
Acquisition of intangibles	0	−3	−540,000	0	0
Net cash (used in) provided by investing activities	−10	124	−10	−19	−14
Proceeds from issuance of and borrowings on long-term debt	0	0	70	0	0
Repayment of long-term debt	0	−50	−45	0	−20
Deferred financing costs on long-term debt	−680,000	0	−751,000	0	0
Principal payments on financing arrangement	−148,000	0	0	—	—
Proceeds from financing arrangement	6	0	0	—	—
Payment of acquisition related contingent consideration	−5	−15	0	0	—
Repurchase of common stock	−2	0	0	—	—
Proceeds from exercise of stock options and employee stock purchase plan	933,000	752,000	1	3	3
Net cash (used in) provided by financing activities	−255,000	−64	25	8	−17
Effect of exchange rate changes on cash and cash equivalents	398,000	125,000	43,000	−518,000	330,000
Increase (decrease) in cash and cash equivalents	−20	31	16	−19	−6
Increase (decrease) in accounts payable for purchases of fixed assets	−49,000	−78,000	124,000	14,000	−139,000
Interest	185,000	0	3	562,000	731,000
Income taxes	800,000	455,000	342,000	329,000	313,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro